Soleno Under Serious Scrutiny As Short Seller Alleges PWS Drug Is Overpriced, Unsafe
Soleno Therapeutics Inc. (NASDAQ:SLNO) shares fell on Friday following a short report from Scorpion Capital, which criticized the company's only product, Vykat XR, as overpriced and potentially unsafe for children with Prader-Willi syndrome (PWS).
Benzinga ·